Cas:364-62-5 metoclopramide manufacturer & supplier

Chemical Name:metoclopramide

CAS.NO:364-62-5

Synonyms:Pramin;Imperan;MAXOLON;Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-;Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-;Reglan;Maxeran;EINECS 206-662-9;Plasil;metoclopramide;Benzenecarboximidic acid, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-;Eucil;Primperan;metoclopramidum [INN_la];4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzenecarboximidic acid;4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide,Methoxychloroprocainamide;4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide

Molecular Formula:C₁₄H₂₂ClN₃O₂

Molecular Weight:299.80

HS Code:2924299090

Physical and Chemical Properties:

Melting point:146-148°C

Boiling point:454.8±55.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.545

PSA:67.59000

Exact Mass:

LogP:3.10

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Pramin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pramin Use and application,4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide,Methoxychloroprocainamide technical grade,usp/ep/jp grade.

Related News: One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. metoclopramide manufacturer Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. metoclopramide supplier One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. metoclopramide vendor This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. metoclopramide factory Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.